相关实验视频

Updated: May 5, 2026

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles

Published on: December 23, 2016

针对性纳米输送系统为预防动脉样硬化的β-环氧德克斯和氨酸修饰的向性纳米输送系统

Jinjin Yu¹, Yajing Ma¹, Xinya Zhang¹

¹School of Pharmacy, Xi'an Jiaotong University, Xi'an 710000. China.

ACS applied materials & interfaces

|June 28, 2024

概括

这项研究开发的双载体纳米粒子 (双NP) 来自修改的β-cyclodextrin提供 (-) - epicatechin gallate (ECG) 动脉样硬化斑块. 装有心电图的双NP有效地治疗了小鼠的动脉样硬化,通过减少斑块大小和炎症.

科学领域:

生物医学工程生物医学工程
纳米技术纳米技术
药理学药理学是指药理学的学科.

背景情况:

天然产品在临床治疗中具有低毒性和高活性.
生物聚合物可以被改造成纳米结构,以有针对性地提供活性成分.
动脉样硬化是一种复杂的疾病,其特点是斑块积累和炎症.

研究的目的:

设计一个多功能纳米平台,以有针对性地向动脉样硬化斑块输送 (-) - 皮甲基酸盐 (ECG).
为了合成双载体纳米颗粒 (双NP) 基于改性β-cyclodextrin (β-CD).
在动脉样硬化小鼠模型中评估ECG加载双NP的治疗疗效.

主要方法:

由β-CD合成的乙化环极素 (PH-CD) 和氨酸环极素.
使用溶剂蒸发方法准备的ECG加载双NP.
给 ApoE-/- 食高脂肪饮食的小鼠服用双NP,并评估治疗效果.

主要成果:

双NP有效地清理了反应性氧物种,并调节了巨细胞的行为.
这些纳米粒子抑制了血管光滑肌肉细胞的增殖和迁移.
在体内研究显示治疗小鼠的斑块面积减少,炎症透和不稳定性.

结论:

开发的ECG载荷纳米制剂是动脉样硬化的一种有效和安全的纳米疗法.
对β-CD的多功能修饰使得针对性药物输送到动脉样硬化病变成为可能.
这种纳米平台对治疗心血管疾病充满了希望.

关键词:

针对CD44的目标定位低pH响应的低pH响应自然活性产品自然活性产品有针对性的血管斑块.这是一种β-cyclodextrin.

更多相关视频

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Formulation and Characterization of Bioactive Agent Containing Nanodisks

Published on: March 17, 2023

相关概念视频

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Modified-Release Drug Delivery Systems: Rate-Programmed I

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Oral Drug Delivery Systems: Delayed-Release Systems

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...